TP 102
Alternative Names: TP-102Latest Information Update: 30 Nov 2023
At a glance
- Originator Technophage
- Class Antibacterials; Bacteriophages; Foot disorder therapies; Skin disorder therapies
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetic foot ulcer
Most Recent Events
- 08 Nov 2023 Phase-II clinical trials in Diabetic foot ulcer in USA (Topical) (NCT05948592)
- 17 Jul 2023 Technophage plans a phase II REVERSE2 trial for Diabetic foot ulcer in unknown location (Topical, Liquid) (NCT05948592)
- 05 Sep 2022 Technophage completes a phase I/II trial in Diabetic foot ulcer in Israel (Topical) (NCT04803708)